Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to recolor white patches in vitiligo

NCT ID NCT07533019

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 9 times

Summary

This study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the size of white patches, especially on the face, and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY4005130 (given intravenously)
What this could lead to
If it works, this could point toward a new treatment to restore skin color in people with vitiligo.
What could go wrong
This is an early phase 2 proof-of-concept study with only 60 participants. It may not show clear benefit, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible participants must have the following at both screening and baseline: * A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months * Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet * BSA involvement of ≥0.5% on the face * F-VASI ≥0.5 and T-VASI ≥3, and * Either active or stable disease at both screening and baseline Exclusion Criteria: * Participants who have other types of vitiligo that are not considered active or stable vitiligo * Currently have active forms of other disorders of pigmentation * Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment * Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved * Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening * Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data * Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo (NSV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized vitiligo vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-segmental vitiligo (NSV) Vitiligo

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    35 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Accurate Clinical Research, Inc

    RECRUITING

    Humble, Texas, 77346, United States

  • Advanced Medical Research, PC.

    RECRUITING

    Sandy Springs, Georgia, 30328, United States

  • Anima Diepenbeek

    RECRUITING

    Diepenbeek, 3590, Belgium

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Center For Dermatology Clinical Research, Inc.

    RECRUITING

    Fremont, California, 94538, United States

  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman

    NOT_YET_RECRUITING

    Liège, 4000, Belgium

  • Centrum Badan Klinicznych PI-House sp. z o.o.

    RECRUITING

    Gdansk, 80-546, Poland

  • Centrum Medyczne Ginemedica

    RECRUITING

    Wroclaw, 50-414, Poland

  • Clinical Research Partners, LLC

    RECRUITING

    Richmond, Virginia, 23226, United States

  • Cura Clinical Research - Oxnard

    RECRUITING

    Oxnard, California, 93030, United States

  • Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway

    RECRUITING

    Santa Clarita, California, 91355, United States

  • Dar Clinical Research - Ottawa - Hunt Club Road

    RECRUITING

    Ottawa, K1V 1C1, Canada

  • Dawes Fretzin Clinical Research Group, LLC

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • DermEffects

    RECRUITING

    London, N6H 5L5, Canada

  • Dermedic Jacek Zdybski

    RECRUITING

    Ostrowiec Świętokrzyski, 27-400, Poland

  • Diamond Clinic

    RECRUITING

    Krakow, 31-559, Poland

  • Equity Medical

    RECRUITING

    The Bronx, New York, 10455, United States

  • Hangzhou Third People's Hospital

    RECRUITING

    Hangzhou, 310009, China

  • Health Clinical Research, LLC

    RECRUITING

    Miami, Florida, 33189, United States

  • INTERMED Groupe Sante

    RECRUITING

    Chicoutimi, G7H 7Y8, Canada

  • Jordan Valley Dermatology & Research Center

    RECRUITING

    South Jordan, Utah, 84095, United States

  • K2 Medical Research - Tampa

    RECRUITING

    Tampa, Florida, 33634, United States

  • Medical Dermatology Specialists

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • Northridge Clinical Trials

    RECRUITING

    Northridge, California, 91325, United States

  • Peking University People's Hospital

    RECRUITING

    Beijing, 100034, China

  • Research Toronto

    RECRUITING

    Toronto, M4W 2N4, Canada

  • Revival Research Institute, LLC

    RECRUITING

    Troy, Michigan, 48084, United States

  • SIMa Recherche

    NOT_YET_RECRUITING

    Verdun, H4G 2L8, Canada

  • Saguaro Dermatology - Phoenix

    RECRUITING

    Phoenix, Arizona, 85008, United States

  • Shanghai Skin Disease Hospital

    RECRUITING

    Shanghai, 200071, China

  • Stracskin

    RECRUITING

    Portsmouth, New Hampshire, 03801, United States

  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue

    RECRUITING

    San Antonio, Texas, 78235, United States

  • The Centre for Dermatology

    RECRUITING

    Richmond Hill, L4B 1A5, Canada

  • The University of Hong Kong-Shenzhen Hospital

    NOT_YET_RECRUITING

    Shenzhen, 518053, China

  • UZ Gent

    NOT_YET_RECRUITING

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.